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Abstract
Serum cystatin C (Cys C) has a number of advantages over serum creatinine in the evaluation of kidney function.
Apart from Cys C level itself, several formulas have also been introduced in different clinical settings for the estimation of
glomerular filtration rate (GFR) based upon serum Cys C level. The aim of the present study was to compare a serum Cys
C-based equation with Cockcroft-Gault serum creatinine-based formula, both used in the calculation of GFR, in patients
receiving amphotericin B. Fifty four adult patients with no history of acute or chronic kidney injury having been planned
to receive conventional amphotericin B for an anticipated duration of at least 1 week for any indication were recruited.
At three time points during amphotericin B treatment, including days 0, 7, and 14, serum cystatin C as well as creatinine
levels were measured. GFR at the above time points was estimated by both creatinine (Cockcroft-Gault) and serum Cys
C based equations. There was significant correlation between creatinine-based and Cys C-based GFR values at
days 0 (R = 0.606, P = 0.001) and 7 (R = 0.714, P < 0.001). In contrast to GFR estimated by the Cockcroft-Gault equation,
the mean (95 % confidence interval) Cys C-based GFR values at different studied time points were comparable within
as well as between patients with and without amphotericin B nephrotoxicity. Our results suggested that the Gentian
Cys C-based GFR equation correlated significantly with the Cockcroft-Gault formula at least at the early time period of
treatment with amphotericin B.
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Introduction
Serum cystatin C (Cys C), a 13 kDa non-glycosylated
protein with cysteine protease inhibitor activity, has been
proposed as an alternative marker to creatinine for
assessing kidney function [1]. It lacks a number of serum
creatinine drawbacks such as being influenced by non-
renal factors including age, gender, muscle mass, and
physical activity [2, 3]. Dose adjustment of many medi-
cations such as antibacterials depends on patients’
glomerular filtration rate (GFR). Direct measurement of
GFR, using urinary inulin clearance and the plasma
99mTc-DTPA or 125-iothalamate is cumbersome, costly,
and not readily available [4].
Besides Cys C level itself, different formulas have also
been introduced in different clinical settings such as
kidney transplant recipients [5], critically ill patients [6],
chronic kidney disease [7], newborns [8], and the elderly
[9] for the estimation of GFR, based upon Cys C serum
level. In contrast to Cockcroft-Gault (CG) and Modifica-
tion of Diet in Renal Disease (MDRD) formulas, which
need several variables such as age and sex for calcula-
tion, Cys C-based equations are mainly dependent only
on serum Cys C levels [10]. To best of our knowledge,
these equations have not been investigated well enough
in drug-induced acute kidney injury (AKI) conditions.
The aim of the present preliminary study was to com-
pare a serum Cys C-based equation with the classic and
prominent CG serum creatinine-based formula, both
used for the calculation of GFR, in patients receiving
amphotericin B (AmB).
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Methods
The data of this study was extracted from a multicentre
randomized, double-blinded, placebo-controlled, clinical
trial (ID: IRCT201107233449N8) that assessed the ef-
fectiveness of oral N-acetylcysteine (NAC) co-treatment
with AmB in preventing major features of AmB nephro-
toxicity [11]. Carried out in a 15-months period, from
early August 2012 to November 2013, at three university
health-care settings affiliated to Tehran University of
Medical Sciences, Tehran, Iran, the study included 54
adult individuals with no documented history of AKI or
chronic kidney disease, having been planned to receive
conventional AmB for an anticipated duration of at least
1 week for any indication. They were given either placebo
or 600 mg oral NAC twice daily during the treatment
course of AmB. The institutional review boards and the
medical ethics committees of all hospitals approved the
study and all patients or their family members signed and
approved a written informed consent form.
At days 0, 7, and 14 of AmB treatment, serum Cys C as
well as creatinine levels were measured. Serum creatinine
level was determined by an Auto-analyzer (Biotechnica
BT-3000, Italy) based on the modified Jaffe colorimetric
reaction. Serum Cys C level was measured by the tur-
bidimetric method (Gentian, Moss, Norway). GFR at
days 0, 7, and 14 was calculated by the CG formula
[(140–age) × (Body weight) × (0.85 if female)/(serum
creatinine × 72)] [12]. CG values were adjusted by
body surface area of relevant patients and reported as
ml/min/1.73 m2. Besides CG, GFR at the above time
points was also estimated by the serum Cys C-based
equation, provided in the package insert of Gentian assay
kit (79.901/Serum Cys C1.4389) [13]. AmB nephrotoxicity
was defined by either a 50 % or more decline in the esti-
mated GFR according to the CG formula or the doubling
of serum creatinine from the baseline values [14].
Statistical analyses
The possible correlation between creatinine-based and
Cys C-based GFR values at days 0, 7, and 14 were assessed
by the Pearson correlation test. Comparison of the mean
values (95 % confidence interval [CI]) of calculated
creatinine-based as well as Cys C-based GFR at the
above time points within and between patients with
and without AmB nephrotoxicity was done by the one-way
analysis of variance (ANOVA) with repeated measures. P
values < 0.05 were considered statistically significant. Statis-
tical analyses were carried out by the SPSS (Statistical
Package for the Social Sciences) version 20 software.
Results
Among 54 patients randomly allocated into either pla-
cebo or NAC receiving group, 23 (42.59 %) developed
AmB nephrotoxicity. The mean ± standard deviation
creatinine-based GFR values at days 0, 7, and 14 were
92.94 ± 42.04, 92.21 ± 45.92, and 54.29 ± 20.63 ml/min/
1.73 m2, respectively. The Cys C-based GFR value was
73.66 ± 34.24 ml/min/1.73 m2 at day 0, 78.19 ± 41.37 ml/
min/1.73 m2 at day 7, and 58.36 ± 25.76 ml/min/1.73 m2
at day 14.
As depicted in Fig. 1, there was significant correlation
between creatinine-based and Cys C-based GFR values at
days 0 (R = 0.606, P = 0.001) and 7 (R = 0.714, P < 0.001).
In contrast, the correlation of these values at day 14 was
not statistically significant (R = 0.496, P < 0.071).
According to results of ANOVA with repeated measure
analysis (Table 1 & Fig. 2), the mean (95 % CI) creatinine-
based GFR at day 14 was significantly lower than that at
day 7 in patients who developed AmB nephrotoxicity
(P = 0.024). Furthermore, the mean (95 % CI) decrease
in creatinine-based GFR values at day 14 compared to
day 0 (−50.457 [−89.477 to-11.437] ml/min/1.73 m2) as
well as day 14 versus day 7 (−37.857 [−63.514 to−12.2]
ml/min/1.73 m2), were statistically significant between in-
dividuals with and without AmB nephrotoxicity (P = 0.016
and P = 0.007, respectively). In contrast to creatinine-
based calculated GFR, the mean (95 % CI) Cys C-based
GFR values at different studied time points were com-
parable within as well as between patients with and
without AmB nephrotoxicity.
Discussion
Although studied extensively, Cys C-based GFR equations
have not generally been introduced into routine clinical
practice yet. Considerable heterogeneity between relevant
GFR equations can be partially taken into account for this
matter [15]. Substantial heterogeneity between Cys C-
based GFR equations can be in turn attributed to four
major factors including: (1) study population differences,
(2) different gold standard methods of GFR measure-
ments, (3) lack of international standardized calibration
for measurement of Cys C, and (4) variation in exploited
analytical techniques as well as reagents [10]. Regarding
the first factor involved, elevated body mass index (BMI)
can be associated with an increase in the Cys C concen-
tration by about 10 %. Furthermore, serum Cys C con-
centrations have been reported to be lower in females than
males (about 9 %) [15]. In the present study, no gold stand-
ard method was used for determining GFR because of both
financial and technical problems.
Regarding the last two factors, three major techniques
including particle-enhanced nephelometric assay (PENIA),
particle enhanced turbidimetric assay (PETIA), and
enzyme-linked immunosorbent assay (ELISA) are com-
monly used for determining Cys C. A meta-analysis on
46 articles published until December 31, 2001, revealed
that immunonephelometric methods of Cys C assay
produced significantly greater correlations with GFR
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than other assay methods (r = 0.846 versus r = 0.784,
respectively; P < 0.001) [16]. In a study on 80 healthy
volunteers and 20 patients with renal and/or heart disease,
the mean difference between ELISA and PETIA or ELISA
and PENIA was 0.65 ± 0.63 μg/ml and 0.58 ± 0.53 μg/ml,
respectively [17]. Interestingly, Tidman et al. demon-
strated that serum Cys C concentrations obtained by
the Gentian method were approximately 10 % lower
than the DAKO method within the normal GFR range.
They also reported that among Cys C-based GFR for-
mulas examined in 644 patients, the former Orebro-
cyst Gentian equation (100/serum Cys C—14) had the
highest accuracy [10].
The Cys C-based GFR equation used in our study was
derived from Flodin et al. investigation on 160 patient sam-
ples aged above 15 years. Linear regression analysis showed
that there was strong correlation between Gentian Cys C
assay using a chemistry instrument (Architect ci8200) and
iohexol clearance (R2 = 0.956) [18]. Lack of significant cor-
relation between creatinine-based and Cys C-based GFR
values only at day 14 but not days 0 and 7 of AmB treat-
ment in our cohort, may be due to the limited number of
patients (only 16) that remained in the study at this time
point. It is noteworthy that considering only correlation
coefficient in our survey seems inadequate and precision,
accuracy, and relative difference should also be calculated
to compare these two formulas properly. The pattern of
Cys C-based GFR values decreased continuously during
the study in patients with AmB nephrotoxicity; but these
changes were not statistically significant in contrast to
creatinine-based GFR values. This may be justified by the
limited number of serum Cys C level measurements at
Fig. 1 The possible correlation between serum creatinine-and serum cystatin C-based GFR values at days 0, 7, 14 of amphotericin B treatment
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Table 1 Mean (95 % confidence interval) changes of creatinine-and serum cystatin C-based GFR values at days 0, 7 and 14 of amphotericin B treatment within and between
patients with and without AmB nephrotoxicity
Time point Day 7 vs. Day 0 Day 14 vs. Day 0 Day 14 vs. Day 7
Creatinine-based GFR (ml/min/1.73 m2)
Mean (95 % confidence interval) difference values in patients
with nephrotoxicity [P value]
-6.258 (−82.997 to 70.480) [1] -66.401 (−150.289 to 17.487) [0.122] -60.143 (−110.816 to-9.470) [0.024]
Mean (95 % confidence interval) difference values in patients
without nephrotoxicity [P value]
-18.942 (−70.939 to 33.055) [0.829] -34.514 (−177.143 to 48.116) [0.656] -15.571 (−74.111 to 42.968) [1]
Mean (95 % confidence interval) difference values between
two groups [P value]
-12.6 (−43.318 to 18.118) [0.389] -50.457 (−89.477 to-11.437) [0.016] -37.857 (−63.514 to−12.2) [0.007]
Cystatin C-based GFR (ml/min/1.73 m2)
Mean (95 % confidence interval) difference values in patients
with nephrotoxicity [P value]
-4.3 (−108.050 to 99.45) [1] -42.943 (− 103.840 to 17.954) [0.179] -38.643 (−96.965 to 19.679) [0.217]
Mean (95 % confidence interval) difference values in patients
without nephrotoxicity [P value]
-19.357 (−59.401 to 20.686) [0.489] -9.729 (−56.979 to 37.521) [1] 9.629 (−48.990 to 68.247) [1]
Mean (95 % confidence interval) difference values between
two groups [P value]















only three time points during AmB treatment, high intrain-
dividual variability of serum Cys C, and absence of a gold
standard method for measuring GFR.
In conclusion, our preliminary findings suggested that
the Gentian Cys C-based GFR calculation equation
correlated significantly with CG formula at least at the
early time period of AmB treatment. However, the con-
tinuous decreasing trend in the mean (95 % CI) values
of Cys C-based GFR at the studied time points was not
statistically significant in patients who developed AmB
Fig. 2 Changing pattern in creatinine-and serum cystatin C-based GFR values at three time points in patients with and without amphotericin
B nephrotoxicity
Karimzadeh and Khalili DARU Journal of Pharmaceutical Sciences  (2016) 24:16 Page 5 of 6
nephrotoxicity. Measuring serum Cys C level at more
frequent and closer time points and exploiting a gold
standard method for measuring GFR can be considered
for future studies in the comparison of serum Cys C-
based equations with serum creatinine-based formulas
used for the calculation of GFR in patients receiving
nephrotoxic medications such as AmB.
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